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Adeno-associated virus (AAV) replication (Rep) proteins are pleiotropic effectors of viral DNA replication, RNA transcrip-
tion, and site-specific integration into chromosome 19. In addition to regulating AAV gene expression, the Rep proteins
modulate expression of a variety of cellular and viral genes. In this report we investigate Rep-mediated effects on expression
of the adenovirus (Ad) E2a gene and the Ad major late promoter. We have found that all four Rep proteins repress E2a
expression at the protein level, with Rep40 showing the weakest repression. Mutations in the purine nucleotide binding (PNB)
site weakened each of the protein’s abilities to repress expression. Analysis of steady-state E2a mRNA showed that Rep
proteins decreased mRNA levels, but to a lesser extent than E2a protein levels. Analysis of mRNA stability demonstrated that
neither Rep78 nor Rep52 affected E2a mRNA stability, suggesting that the decrease in mRNA is due to Rep-mediated
inhibition of Ad E2a transcription. To determine if Rep68 proteins could directly inhibit RNA transcription, we performed in
vitro transcription assays using HeLa nuclear extracts supplemented with Rep68 and Rep68PNB. We demonstrate that
Rep68, but not mutant Rep68PNB, blocked in vitro transcription of a template containing the Ad major late promoter. These
results provide insight into how AAV and its encoded Rep proteins interact with Ad and provide a model system for the studyINTRODUCTION
Adeno-associated virus (AAV) is a defective human
parvovirus that normally requires a helper virus to com-
plete its replication cycle (reviewed in Muzyczka and
Berns, 2001). A variety of DNA viruses provide essential
helper functions for AAV replication but adenovirus (Ad)
is its most efficient helper (Atchison et al., 1965; Casto et
al., 1967a; Atchison, 1970; Dolin and Rabson 1973; Buller
et al., 1981; McPherson et al., 1985; Walz et al., 1997;
Ogston et al., 2000). One recent report suggests that AAV
replicates autonomously in differentiating keratinocytes
(Meyers et al., 2000). AAV integration into the long arm of
chromosome 19 occurs in the absence of a helper virus
co-infection and is the means by which the virus estab-
lishes latency in the infected cell (Muzyczka and Berns,
2001).
The AAV replication, rep, gene encodes four pleiotro-
pic nonstructural proteins. These proteins, Rep78,
Rep68, Rep52, and Rep40, are referred to as Rep pro-
teins because expression of the larger proteins is re-
quired for viral DNA replication. The Rep proteins also
modulate viral gene expression, site-specific integration
into the chromosome 19 locus, and cellular gene expres-
sion (Muzyczka and Berns, 2001). The Rep78 and Rep68345roles in viral gene expression include repression of tran-
scription from the p5 promoter in the presence and
absence of Ad co-infections (Beaton et al., 1989; Kyostio
et al., 1995; Pereira et al., 1997), activation of transcription
from the p19 and p40 promoters in the presence of Ad
co-infection (McCarty et al., 1991; Pereira et al., 1997),
and suppression of protein translation of cap gene
mRNA (Trempe and Carter, 1988). In plasmid cotransfec-
tion experiments, rep gene expression inhibits gene ex-
pression from some heterologous promoters (Antoni et
al., 1991; Horer et al., 1995; Khleif et al., 1991; Labow et
al., 1987) and increases expression from the c-sis gene
(Wonderling and Owens, 1996) and the CMV early pro-
moters (Wonderling et al., 1997).
AAV and the other parvoviruses have long been known
to inhibit oncogene-mediated cellular transformation and
the proliferation of infected cells. Helper virus-free AAV
infection alters expression of several cell cycle-regulated
genes (Hermanns et al., 1997), promotes differentiation
(Klein-Bauerschmitt et al., 1992; Winocour et al., 1992),
and induces a cell cycle block (Winocour et al., 1988).
The AAV-induced cell cycle block is correlated with a
decrease in retinoblastoma (Rb) protein phosphorylation
and an increase in p21Cip gene expression (Hermanns et
al., 1997). AAV inhibitory effects are also exerted on the
helper virus in co-infected cells in that AAV, but notof AAV and host-cell interactions. © 2002 Elsevier Science (USA
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1979). AAV blocked Ad DNA replication more effectively
than ultraviolet light inactivated AAV or an AAV vector
(Jing et al., 2001). These combined results indicate that
amplification of the AAV genome or AAV gene expression
is essential for Ad inhibition. The AAV effects on Ad-
induced tumorigenicity and cellular transformation have
been attributed to the AAV terminal repeat sequences
and AAV gene expression (de la Maza and Carter, 1981;
Khleif et al., 1991); however, the effects on Ad replication
have been attributed to expression of the AAV replication
(rep) gene (Weitzman et al., 1996). A recent report sug-
gests that AAV alters cellular E2F expression in unin-
fected and Ad-infected cells (Batchu et al., 2001). It was
also proposed that AAV Rep78 stabilizes the pRb–E2f
complex and binds to DNA elements in the E2F tran-
scription promoter. In another report, Rep78 arrested
cells in S phase by a novel mechanism involving the
ectopic accumulation of active pRb (Saudan et al., 2000).
In order to further define the interactions between AAV
and its helper virus, we have begun a study of the
inhibitory effects of AAV on Ad replication and gene
expression. We present evidence that the AAV Rep pro-
teins inhibit Ad E2a gene expression at the protein and
mRNA levels. We also provide evidence that the effects
on E2a mRNA accumulation may be due to effects on
transcription rather than on mRNA stability.
RESULTS AND DISCUSSION
AAV rep vectors and protein expression
Individual Rep vectors were constructed to insure that
only one of the four Rep proteins was predominantly
expressed in plasmid-transfected 293 cells. A Met3 Gly
change was introduced into the Rep78 and Rep68 plas-
mids at the initiation codon for the Rep52/40 proteins to
create pCDMRep78G and pCDMRep68G, respectively.
This change results in the expression of fully functional
Rep78/68 proteins and no expression of Rep52/40 (Che-
janovsky and Carter, 1989). A mutation was introduced
into all four Rep plasmids to inactivate the purine nucle-
otide binding site (Chejanovsky and Carter, 1990). Figure
1 shows diagrams of the pCDMRep plasmids used in
this study. Ad-infected 293 cells were transfected with
the eight plasmids to verify Rep protein expression (Fig.
2). The Rep78/68 proteins were immunoprecipitated with
Rep-specific antisera because a cross-reacting cellular
protein of approximately 68 kDa is frequently detected in
immunoblot analyses and comigrates with the Rep68
protein (Trempe et al., 1987). The immunoprecipitated
proteins were then analyzed by immunoblot analyses.
The immunoblot in Fig. 2 shows that the purine nucleo-
tide binding (PNB) site mutant versions of the Rep pro-
teins were expressed at levels similar to those of the
wild-type form of the protein.
AAV Rep protein effects on gene expression from the
E2a transcription promoter
We have shown that Ad E2a expression is repressed
in AAV and Ad co-infected HeLa cells and in a 293-
derived cell line (Neo6) that inducibly expresses the AAV
rep gene (Jing et al., 2001). All four Rep proteins are
expressed in a co-infection and the Rep78 and Rep52
proteins are expressed upon induction in Neo6 cells
(Yang et al., 1994). To determine if the individual Rep
proteins affect expression from the E2a promoter, 293
cells were transfected with the Rep plasmids and a
luciferase gene reporter under the control of the Ad E2a
transcription promoter, pE2a-luc. Two days after trans-
FIG. 1. Rep expression vectors. The drawing shows the individual
Rep proteins expressed in cell culture from pCDM8-derived plasmids.
The numbers are the locations in the AAV2 genome of the Rep78/68
initiation codon (321), the Met 3 Gly change in Rep78/68 (992), the
mutation in the PNB site (1338), the Rep78/52 termination codon (2183),
the major splice site (1906–2228), and the Rep68/40 termination codon
(2260). The location of the XhoI linker in Rep1097 is indicated.
FIG. 2. Rep protein expression in 293 cells. The plasmids described
in Fig. 1 were transfected into 293 cells. Rep proteins were immuno-
precipitated with Rep-specific antisera (Trempe et al., 1987), separated
on SDS–PAGE, and immunoblotted with Rep antisera. The first five
lanes containing the IgG band were the samples that were immuno-
precipitated prior to gel electrophoresis. Alternatively cytoplasmic ex-
tracts were prepared, separated by SDS–PAGE, and analyzed by im-
munoblot. The locations of Rep proteins and IgG are indicated on the
left. The locations of molecular weight standards are shown on the
right.
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fection, cellular extracts were prepared and luciferase
enzyme activity was determined. Figure 3 shows that all
of the Rep-expressing plasmids suppress expression
from the Ad E2a promoter and that Rep40 is the weakest
suppressor. Each of the PNB mutant plasmids allowed
higher activity than their corresponding wild-type plas-
mids. These results are consistent with other studies
that have examined the ability of the individual Rep
proteins to repress gene expression from homologous
and heterologous promoters (Kyostio et al., 1995; Horer
et al., 1995).
To determine if comparable inhibitory effects are real-
ized with the complete Ad5 E2a gene, similar transfec-
tion experiments were performed using a plasmid con-
taining a 5768-bp BamHI–EcoRI DNA fragment from Ad5
that contains the entire E2a gene. 293 cells were co-
transfected with the E2a and Rep-expressing plasmids
and E2a protein expression was examined by immuno-
blot analysis (Fig. 4). Compared to the pCDM8 vector and
pRep1097 null mutant, the Rep78, Rep68, and Rep52
proteins were the strongest suppressors of expression
from the E2a promoter. The PNB mutant versions of the
proteins were weaker suppressors than the wild type. In
multiple repeats of this experiment, the Rep52 and Rep78
proteins were the strongest suppressors of E2a protein
expression. These results are comparable to those ob-
tained in the luciferase assays in that the PNB mutant
versions of the Rep proteins were weaker suppressors of
protein expression.
To determine if the diminished E2a protein expression is
reflected in the steady-state E2a mRNA levels, 293 cells
were transfected with the various Rep protein plasmids and
the E2a gene plasmid, total RNA was isolated after 48 h,
and mRNA levels were measured by Northern hybridiza-
tion. Prior to the Northern analyses, E2a protein levels were
examined by immunoblot and in all cases the levels of E2a
were comparable to those observed in the immunoblot
shown in Fig. 4 (data not shown). In the mRNA analysis, all
of the Rep proteins except Rep68PNB and Rep40PNB re-
duced the level of E2a mRNA (Fig. 5). We consistently
observed that Rep52, followed by Rep78, is the strongest
suppressor of E2a mRNA levels as well as luciferase and
E2a protein expression. In contrast, Horer et al. found that
Rep78 and Rep68 suppressed mRNA levels from the HIV
long terminal repeat and the HPV18 URR promoters,
whereas Rep52 had only a modest effect in HeLa cells
FIG. 3. AAV Rep protein effects on E2a-luc gene expression. The
pE2a-luc plasmid was transfected into 293 cells with the indicated AAV
Rep plasmids. 48 h later extracts were prepared and analyzed for
luciferase activity. The results are reported as relative light units (RLU)
per microgram of protein.
FIG. 4. AAV Rep protein effects on E2A protein expression. The pAd5E2a plasmid was cotransfected into 293 cells with the indicated AAV Rep
plasmids. 48 h later the cultures were harvested and analyzed for E2A expression by SDS–PAGE and immunoblot using anti-E2ADBP antibody. The
E2A band is shown in the immunoblot at the top. A densitometer scan of the immunoblot is shown at the bottom.
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(Horer et al., 1995). The inability of Rep52 to site-specifically
bind to DNA suggests that it may inhibit gene expression by
a mechanism different from that of Rep78 or Rep68. Lucif-
erase activity from the HIV and HPV promoters was re-
pressed by Rep78 followed by Rep52, Rep68, and Rep40
(Horer et al., 1995). Thus, Rep protein effects on mRNA
levels and protein expression vary among transcription
promoters and host cells.
It is interesting to note here that although Rep68PNB
does not show any suppression of E2a mRNA, it sup-
pressed expression of the E2a protein shown in Fig. 4
and luciferase expression from the E2a promoter shown
in Fig. 3. These results suggest that Rep68PNB has lost
the ability to suppress mRNA accumulation, and perhaps
transcription, yet retains its ability to suppress mRNA
translation. Thus Rep ATPase or helicase activity may not
be required for inhibition of translation.
Ad5E2a mRNA stability
The quantity of any protein synthesized per unit of time
depends on the abundance of its mRNA and the effi-
ciency with which that mRNA is translated. In turn, mRNA
abundance depends on the rate at which that mRNA is
transcribed, spliced, processed, transported, and de-
graded (Peltz et al., 1991). We performed an analysis of
E2a mRNA stability to determine if the inhibition of E2a
mRNA accumulation is due to effects on mRNA turnover
rather than an effect on transcription. 293 cells were
cotransfected with the Rep78, Rep52, and Ad5E2a plas-
mids. Forty hours posttransfection, actinomycin D was
added to the cultures. At 2-h intervals up to 12 h, total
RNA was isolated and analyzed by gel electrophoresis
and Northern hybridization. Figure 6 contains a repre-
sentative Northern hybridization and densitometer anal-
ysis of one such experiment. At time zero, E2a mRNA in
the presence of Rep78 or Rep52 is 25–30% of the level of
mRNA in cells cotransfected with the pCDM8 control
vector. With increasing times of actinomycin exposure to
block new transcription, there was a decrease in E2a
mRNA level in all samples. The half-life of the mRNA in
the pCDM8-transfected cultures is approximately 10 h,
whereas in the Rep78- and Rep52-transfected cultures
the half-life is approximately 11–12 h (Fig. 6C). Although
actinomycin is known to have toxic effects on cells in
culture (Peltz et al., 1991) the lack of obvious degradation
of the 28S and 18S rRNA (Fig. 6B) indicates that the total
RNA integrity is not altered in these incubations. These
results suggest that the stability of E2a mRNA is not
altered by Rep78 or Rep52 and that the decrease in E2a
mRNA is likely due to a Rep effect on transcription.
Rep protein effects on mutant Ad E2a promoters
Our results thus far suggest that the AAV Rep proteins
decrease the steady-state level of Ad E2a mRNA but do
not alter mRNA stability. This apparent Rep-mediated
transcription effect may be regulated via specific tran-
scription factor binding sites in the E2a promoter. To
determine whether any of the known transcription factor
binding sites in the E2a promoter are involved in sup-
pression, we obtained a series of plasmids containing
FIG. 5. AAV Rep protein effects on E2a mRNA levels. The pAd5E2a plasmid was cotransfected onto 293 cells with the indicated AAV Rep plasmids.
48 h later the cultures were harvested and E2a mRNA levels were analyzed by Northern hybridization. The E2a mRNA band is shown in the Northern
blot at the top. A densitometer scan of the Northern blot is shown at the bottom.
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wild-type and deletion mutant versions of the Ad E2a
promoter attached to the chloramphenicol acetyltrans-
ferase reporter gene, E2a-Cat (Loeken and Brady, 1989).
A diagram of the wild-type and deletion mutant promoter
elements is shown in Fig. 7. Each of the E2a-Cat plas-
mids was cotransfected onto 293 cells in the presence of
the Rep78, Rep68, or Rep52 plasmids. Forty-eight hours
later cultures were harvested, cellular extracts were pre-
pared, and Cat enzyme activity was determined. If the
Rep proteins reduce expression by altering the ability of
one of the transcription factors to stimulate promoter
activity, then we would expect to see a change in relative
Cat activity if that transcription factor binding site is
removed from the promoter. The results in Table 1 are
normalized to 100% for each of the four reporter plas-
mids. As expected, the wild-type plasmid expressed the
most Cat activity followed by E2ATF (38% of wt), E2E2F
(17% of wt), and E2TATA (12% of wt) (results not shown).
Deletion of the ATF, E2F, or TATA DNA elements did not
result in an increase in gene expression in the presence
of the wild-type Rep plasmids compared to the vector
plasmid (pCDM8). Although reports in the literature sug-
gest that Rep proteins may antagonize transcription pro-
FIG. 6. AAV Rep protein effects on E2a mRNA stability. The pAd5E2a plasmid was cotransfected onto 293 cells with pCDM8, pCDMRep52, or
pCDMRep78. 40 h posttransfection, actinomycin D was added to each dish at a concentration of 5 g/ml. The cells were harvested 0, 2, 4, 8, and
12 h later and total RNA was isolated and analyzed by Northern hybridization. (A) Northern analyses showing the level of E2a mRNA at each of the
indicated time points. (B) The gel was stained with ethidium bromide prior to RNA transfer to filter paper. The locations of the 18S and 28S rRNA
species are indicated. (C) The relative levels of mRNA produced for the three cotransfections was determined by densitometer tracing of the Northern
blot in A above. The amount of E2a mRNA at 0 h in the pCDM8 cotransfection was designated 100%. The amounts of mRNA in the other transfections
are reported as a percentage of the pCDM8 cotransfection. These results are representative of three independent plasmid transfections.
FIG. 7. Wild-type and mutant E2a-Cat plasmids. The wild-type E2a
promoter attached to the Escherichia coli Cat gene is shown at the top.
The ATF, E2F, and TATA deletion mutants are shown.
TABLE 1
Rep-Mediated Inhibition of Wild-Type and Mutant E2a
Promoter Activitya
E2a wt E2a ATF E2a E2F E2a TATA
pCDM8 100 100 100 100
pCDMRep78 9.4 4.6 13.4 5.2 13.4 4.0 10.2 2.9
pCDMRep68 12.0 4.3 19.9 12.1 12.8 3.9 19.0 5.8
pCDMRep52 7.4 0.3 14.9 6.4 12.7 1.1 10.7 1.0
a 293 cell cultures were cotransfected with the various E2a promoter
Cat plasmids and Rep plasmids. 48 h later cultures were harvested and
Cat assays performed as described in the text. The values are reported
as percentage of activity compared to the pCDM8 vector-transfected
cultures  standard deviation.
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moters containing sites for ATF (Chiorini et al., 1998;
DiPasquale et al., 1998), TATA (Su et al., 2000; Hermonat
et al., 1998), and E2F (Batchu et al., 2001), it is clear that
removal of only one of these binding sites from the E2a
promoter is insufficient to alleviate Rep repression. Thus
Rep-mediated inhibition of the Ad E2a promoter is not
solely dependent upon one of these specific transcrip-
tion factor binding sites.
Rep68 inhibits in vitro transcription of the Ad major
late promoter
The diminution of E2a mRNA levels and the lack of an
effect on mRNA stability strongly suggest that the Rep
proteins inhibit transcription. However, the lack of an
effect on expression from the E2a promoter mutants
suggests that if the Rep proteins inhibit transcription, the
target of Rep action may be other factors in the general
transcription machinery or some other DNA element in
the plasmid vector. To determine if purified Rep68 protein
affects the enzymatic events in transcription we per-
formed in vitro transcription assays using HeLa nuclear
extracts (Dignam et al., 1983) and a plasmid, pTIGL,
containing a G-free transcription cassette driven by a
minimal Ad major late promoter (AdMLP) (Wang et al.,
1998). We used the AdMLP-driven transcription template
rather than an Ad E2a promoter because of the weak-
ness of the E2a promoter in in vitro assays (Dignam et
al., 1983; Lee and Roeder, 1981; Fire et al., 1981). Two
versions of the AdMLP template were prepared. One
version was a 3104-bp, XbaI-linearized fragment and the
other was the same plasmid that was left uncut by
restriction endonuclease. In vitro transcription in the
presence of increasing amounts of a His-tagged Rep68
protein (Young et al., 2000) resulted in elimination of the
388-nt RNA runoff transcript from the linearized plasmid
(Fig. 8). However, similar amounts of Rep68 that contains
a mutation in the purine nucleotide binding site (Rep68-
PNB) did not repress transcription. The highest concen-
tration of Rep68 also inhibited transcription from the
circular pTIGL plasmid, whereas Rep68PNB did not af-
fect transcription (Fig. 8, lanes 14–17). Transcription from
the AdMLP template was due to RNA polymerase II
because it was completely inhibited by 1 g/ml -aman-
itin (Fig. 8, lanes 11 and 12). The mechanism of this
inhibition remains to be elucidated. However, it is worth
noting that the pTIGL plasmid contains two regions that
are homologous to the AAV Rep78/68 binding site found
in the viral terminal repeat elements. The distal site has
been shown to bind Rep68 in electrophoretic gel mobility
shift assays (McCarty et al., 1994). Therefore it is possi-
ble that Rep68 binding to the template DNA via the Rep
binding sites is necessary for inhibition of transcription.
That the PNB mutant had no effect on transcription sug-
gests that ATP hydrolysis or DNA/DNA or DNA/RNA
helicase activity is essential for suppression.
The experiments presented here have shown that all
four Rep proteins can suppress gene expression from
the Ad E2a transcription promoter in Ad-transformed 293
cells. These studies emulate the early stages of an Ad
and AAV co-infection because of the presence of the
endogenous E1a gene in 293 cells and the introduced
E2a and rep genes. Other results from our lab have
demonstrated that AAV and rep expression inhibits Ad
E2a expression at the protein and mRNA levels during
AAV and Ad co-infection (Jing et al., 2001). These studies
define which of the four Rep proteins may play roles in
suppression of E2a expression in the presence of trans-
activating E1a proteins. The carboxyl terminus of
Rep78/52 would seem to be required for the full effect of
mRNA suppression in vivo. In the absence of the car-
boxyl terminus, the PNB domain in Rep68/40 is neces-
sary for the in vivo mRNA effects and for Rep68, the in
vitro effects as well. The results in Figs. 3–6 and 8
suggest that the PNB domain’s role in suppression of
gene expression is primarily at the level of transcription.
Luciferase and E2a protein levels increase when the
FIG. 8. Rep68 inhibits in vitro transcription of the Ad major late promoter. HeLa nuclear extracts were programmed for in vitro transcription using
transcription templates driven by the cytomegalovirus early promoter (CMV) (lane 1) or the Ad major late promoter (AdMLP) (lane 2). The
XbaI-linearized pTIGL template was used in lanes 2–12. The transcription reactions were supplemented with purified Rep68His (lanes 3–6) or
Rep68His-PNB (lanes 7–10) at final concentrations of 0.032, 0.064, 0.096, and 0.128 g/ml, respectively. Lanes 11 and 12 contain linearized AdMLP
transcription in the absence and presence of 1 g/ml of -amanitin, respectively. Lanes 11–17 contain transcription products from circular pTIGL
plasmid in the absence of added Rep68 (lane13) or in the presence of Rep68 (lanes 14, 15) or Rep68PNB (lanes 16, 17) at final concentrations of 0.064
(lanes 14, 16) and 0.128 g/ml (lanes 15, 17), respectively. The locations of the control 363-nt CMV product and the 388-nt AdMLP products are
indicated at the left.
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PNB mutants are included in transfection compared to
the normal rep genes. These increases in expression
probably result from the increase in mRNA that is evident
in the Northern analyses shown in Fig. 5. In summary, the
carboxyl terminus is required for full mRNA suppression
of E2a expression. The PNB domain augments the
mRNA effect and apparently plays only a minimal role, if
any, in suppression of translation.
In an AAV and Ad co-infection, or in Ad-infected Neo6
cells, there is a two- to threefold decrease in E2a mRNA
(Jing et al., 2001). This level of inhibition is comparable to
the results shown in Figs. 5 and 6 in which we observed
a two- to threefold decrease in E2a mRNA in the pres-
ence of Rep78 and Rep52. Our results are somewhat
similar to those of others in that Rep78 is a strong
suppressor of heterologous gene expression and Rep40
is the weakest suppressor (Horer et al., 1995). However,
differences remain in the inhibitory capabilities of the
Rep proteins because Rep52 is a strong suppressor of
E2a mRNA levels but had only minimal effects on mRNA
from HIV and HPV transcription promoters. The PNB site
in the Rep proteins increases the inhibitory capabilities
but is not the only functional domain required for inhibi-
tion of E2a expression.
The Rep proteins have been reported to associate with
a variety of cellular proteins that are involved in the
regulation of transcription. All three of the predominant
transcription factors that bind to the E2a promoter have
been reported to be affected by the Rep proteins. Rep78
and Rep52 associate with protein kinase X (PrKX) of the
protein kinase A family (Chiorini et al., 1998; DiPasquale
et al., 1998). Rep/PrKX interaction inhibits kinase action
on the ATF transcription factor that in turn prevents ac-
tivation of genes containing ATF regulatory elements.
Rep78 has been reported to bind to TATA box binding
protein (TBP) as well as disrupt TBP binding to the TATA
element (Hermonat et al., 1998; Su et al., 2000). Recently
it has been suggested that Rep expression alters Rb
function and activation of E2F gene expression (Batchu
et al., 2001). Removal of each of these transcription factor
binding sites did not eliminate Rep-mediated suppres-
sion of reporter gene expression. If for example, Rep
proteins acted solely through the TATA box, then we
would have expected that deletion of the TATA box would
have eliminated Rep-mediated repression. That we did
not lose Rep-mediated repression in the E2a-Cat assays
suggests that the individual transcription factor binding
sites are not the sole elements involved in Rep repres-
sion. It is possible that the Rep proteins may act through
some other undefined element in the E2a promoter.
However, we have not been able to detect Rep protein
binding to 291 bp DNA fragment used in the pE2a-Luc
vector (results not shown).
The mechanism of Rep-mediated suppression of gene
transcription has not been well defined. That the elimi-
nation of the known transcription factor binding sites
from the E2a promoter did not eliminate Rep-mediated
repression of Cat activity suggests that Rep proteins may
block transcription via interaction with other known tar-
gets in the initiation or elongation complex. These tar-
gets may be through other components of the transcrip-
tion complex (e.g., PC4) or chromatin (e.g., HMG1).
Rep68-mediated transcription inhibition of the minimal
AdMLP in in vitro assays supports this general hypoth-
esis. Rep protein association with a Rep binding element
on the transcription template may be necessary for sup-
pression of in vitro transcription (Zhan et al., 1999). Such
Rep-specific binding to the pTIGL templates may also be
involved in Rep-mediated inhibition of in vitro transcrip-
tion. The transcription templates used in this work con-
tain one known and a second potential Rep binding site.
Both the linear and the covalently closed circular pTIGL
templates were inhibited by the wild-type Rep68 protein
but not by the PNB mutant version or Rep68. Both pro-
teins can bind to cognate Rep binding sites (Owens et
al., 1991). However, the actinomycin experiments shown
in Fig. 6 imply that Rep78/52 inhibit E2a gene transcrip-
tion. Rep52s inability to bind to known Rep binding sites
argues against the requirement for Rep binding to the
template as a means to inhibit transcription. Clearly,
further experiments are required to identify the mecha-
nism of Rep-mediated inhibition of transcription.
An additional insight into the mechanism of Rep sup-
pression of in vitro transcription comes from our results
showing the requirement for the purine nucleotide bind-
ing site. This requirement suggests that ATPase or heli-
case activities are required for transcription suppres-
sion. A functional PNB domain may be an essential
requirement for transcription suppression because the
Rep68PNB mutant did not decrease E2a mRNA levels in
plasmid transfection assays (Fig. 5). The PNB mutant is
still capable of binding to Rep binding sites (Owens et al.,
1991), therefore Rep binding alone is insufficient for tran-
scription suppression. A possible mechanism to explain
how Rep68 blocks AdMLP transcription in vitro is that the
protein binds to one or both of the Rep binding sites and
induces denaturation of the template, thus disrupting
transcription. Experiments in which the Rep binding sites
have been removed from the transcription template and
Rep52 and Rep40 have been added to the in vitro tran-
scription cocktail are currently under way.
The studies presented here provide new insights into
how AAV and the Rep proteins interact with Ad. There are
several potential Rep binding sites in the Ad2/5 genome.
It is conceivable that Rep binding to one or more of these
sites affects Ad gene expression. However, the effects of
Rep52 on E2a gene expression argue against a simplis-
tic explanation of Rep-mediated inhibition of Ad gene
expression through site-specific DNA binding. Further
experiments are required to fully define AAV’s relation-
ship with its most efficient helper virus.
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MATERIALS AND METHODS
Cells, plasmids, and antibodies
Human 293 cells were originally obtained from the
American Type Culture Collection and were grown in
Eagle minimum essential medium supplemented with
glutamine, penicillin (50 mg/ml), streptomycin (50 mg/ml),
and 10% fetal bovine serum. All cells were maintained as
monolayer cultures at 37°C in a 5% CO2 atmosphere.
The pAd5E2a plasmid was constructed by removing a
5768-bp BamHI to EcoRI DNA fragment from Ad5 (nt
21,563–27,331) and inserting it into the corresponding
sites in pBluescript SK (Stratagene). Plasmid pRep1097
contains a XhoI linker insertion mutation at nucleotide
1097 in the AAV2 genome. It does not express any Rep
protein (Yang et al., 1992, 1994). Plasmid pCDMRep78G
contains the wild-type Rep gene (nt 263–2233 in the
AAV2 genome) cloned in pCDM8 (Invitrogen, Inc.) under
the control of CMV early promoter (Yang et al., 1994). The
G refers to the presence of a Gly codon in place of the
Rep52/40 Met initiation codon at nucleotide 992 (Che-
janovsky and Carter, 1989). The pCDMRep68G plasmid
was constructed by inserting the carboxyl-terminus-encod-
ing region of Rep68 from pNTC28 into the pCDMRep78G
plasmid. The pNTC28 plasmid does not encode Rep78 or
Rep52 because it lacks the major p40 mRNA intron from nt
1908 to 2228 (Chejanovsky and Carter, 1989). The pCDM-
Rep52 plasmid was constructed by removal of AAV rep
gene sequences 263–971 from pCDMRep78. The pCDM-
Rep40 plasmid was constructed from pCDMRep52 in a
manner analogous to the construction of pCDMRep68G.
The PNB site mutant versions of the Rep-expressing plas-
mids were constructed by replacing the normal version of
the PNB with an appropriate restriction endonuclease frag-
ment from pNTC23 which contains a Lys3 His change at
nt 1338–1340 in the AAV2 (Chejanovsky and Carter, 1990).
Plasmid pE2a-Luc contains a 291-bp E2a promoter
element attached to a luciferase reporter gene (Jing et
al., 2001). Plasmid pE2awtCAT containing the Ad E2a
early promoter upstream of a Cat reporter gene and its
corresponding E2F and ATF mutants were obtained from
Dr. J. Brady (Loeken and Brady, 1989). The E2F mutant
lacks nucleotides 64/60 and 40/36 and the ATF
mutant lacks nucleotides 80/76 of the Ad E2a pro-
moter. We constructed a TATA box deletion mutant by
annealing the following oligonucleotides, which lack the
TATA element: 5-GAT CTA GCG CGC AGT ATT TGC TGA
AGA GAG CCT CCG CGT CTT CCA GCG TCG GCC GAA
GCT GAT CT-3 and 5-GAT CAG ATC AGC TTC GGC
GCA CGC TGG AAG ACG CGG AGG CTC TCT TCA GCA
AAT ACT GCG CGC TA. Plasmid pE2awtCAT was cut with
BclI and BglII and ligated to the annealed TATA-less
oligonucleotides.
Plasmid pTIGL containing the AdMLP upstream of a
G-less cassette was a gift from Dr. M. Sawadogo (Wang
et al., 1998).
The pStump68 plasmid was kindly provided by Dr. R. J.
Samulski (Young et al., 2000). To construct pStump68His-
PNB, a 383-bp BamHI–SalI DNA fragment containing rep
gene sequences from 1045 to 1428 was removed from
pCDMRepG68-PNB. The DNA fragment contains the Lys3
His coding change at nt 1338–1340. The 383-bp fragment
was inserted into BamHI/SalI-cut pStump68His. The result-
ing pStump68His-PNB plasmid was transformed in
SG13009 cells, which carry the Escherichia coli lacI gene
and allow for inducible expression using IPTG (Qiagen).
Antibody against Ad 72-kDa DNA binding protein, a
mouse monoclonal IgG (MAb 37-3) was kindly provided by
Dr. I. Kovesdi of GenVec, Inc. AAV Rep protein-specific
polyclonal antibodies were obtained from rabbits immu-
nized with a recombinant Rep protein expressed from E.
coli (Trempe et al., 1987). Alkaline phosphatase-conjugated
anti-rabbit IgG (Cat. No. 31340) was obtained from Pierce
Co.
RNA isolation and Northern blot analysis
Human 293 cells (5  106) in 100-mm dishes were
cotransfected with 5 g of pAd5E2a and 10 g of various
pCDMRep protein-expressing plasmids using the calcium
phosphate method (Ausubel et al., 1989). Forty-eight hours
posttransfection total RNA was isolated using Trizol re-
agent according to the manufacturer’s protocol. Thirty mi-
crograms of total RNA was separated by formaldehyde
agarose gel electrophoresis (Ausubel et al., 1989). RNAwas
transferred to a nitrocellulose membrane and was
crosslinked to the membrane using a UV Stratalinker at a
setting of 1200 J  100. RNA on the filter was hybridized
to an -32P-labeled DNA probe that was labeled using the
random-prime method according to the manufacturer’s pro-
tocol (Boehringer Mannheim). Prehybridizations, hybridiza-
tions, and washings were performed as described (Aus-
ubel et al., 1989). The blot was exposed to X-ray film or to a
Molecular Dynamics phosphorimager. The amount of hy-
bridization signal was determined by the phosphorimager
software or densitometric scanning of X-ray film using a
Kodak Image Station 440CF and Kodak Digital Science 1D
image analysis software.
Steady-state level of mRNA of Ad5E2a gene
293 cells were cotransfected as described above with
pAd5E2a and pCDM8, pCDMRep78, or pCDMRep52.
Forty hours posttransfection, actinomycin D was added
to each dish at a concentration of 5 g/ml. The cells
were harvested 0, 2, 4, 8, and 12 h later and total RNA
was isolated and analyzed by Northern hybridization
described above.
Protein extraction and immunoblot analysis
293 cells (1  106) grown in six-well dishes were
cotransfected using the calcium phosphate precipitation
procedure with 1 g of pAd5E2a and 2 g of each of the
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different AAV Rep plasmids. For examination of Rep pro-
tein expression, the pAdE2a plasmid was not cotrans-
fected. Cells were harvested 48 h later and pelleted by
centrifugation at 1000 g at 4°C for 5 min. The cell pellet
was lysed on ice for 10 min in 200 l of STM-NP buffer
(25 mM sucrose, 10 mM Tris–HCl, pH 8.0, 10 mM MgCl2,
0.5% NP-40, 1 mM PMSF, and 0.1 mM DTT). The lysate
was centrifuged at 2000 g at 4°C for 5 min to obtain a
nuclear pellet. The nuclear pellet was resuspended in
200 l of IPP buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
20 mM EDTA, 0.5% NP-40, 1 mM PMSF, 1 M leupeptin,
1 mM benzamidine, and 1 g/ml pepstatin A) and incu-
bated on ice for 30 min. The nuclear extract was centri-
fuged at 10,000 g at 4°C for 10 min to remove DNA and
nuclear debris. The supernatant was used as the nuclear
extract. The cytoplasmic protein content was measured
using a Bio-Rad protein assay kit.
Nuclear extracts containing equal amounts of protein
were analyzed for E2a, Rep52, and Rep40 expression
using SDS–PAGE and immunoblots as described below.
To determine the level of Rep78, Rep78-PNB, Rep68, and
Rep68-PNB expression, we performed immunoprecipita-
tions followed by SDS–PAGE and immunoblot analysis.
The Rep-specific antibody occasionally detects a cross-
reacting cellular protein that comigrates with Rep68
(Trempe et al., 1987). This contaminant can be eliminated
from the gels by prior immunoprecipitation. Immunopre-
cipitation of Rep78/68 proteins was carried out by first
preadsorbing 175 l of affinity-purified Rep antibody to
75 l of protein A–agarose beads overnight at 4°C with
continuous rotation. The nuclear extract (equivalent to
approximately 1.2  106 nuclei) was treated with SDS to
a final concentration of 1% (w/v) and -mercaptoethanol
to a final concentration of 50 mM. The extract was
heated at 70°C for 10 min, cooled, and diluted 10-fold
with IPP buffer. The nuclear extract was incubated with
the antibody-bound beads overnight at 4°C. The beads
were pelleted by centrifugation at 500 g at 4°C for 5 min.
The beads were washed with IPP buffer and washed
three additional times. After the final wash, the beads
were resuspended in SDS–PAGE sample buffer, boiled,
and pelleted and the released protein was separated on
a 10% SDS–PAGE gel. After electrophoresis the protein
was transferred to a nitrocellulose membrane using a
Bio-Rad semidry transfer unit and immunoblots were
performed using Rep- or E2a-specific antiserum as de-
scribed previously (Yang et al., 1994).
Analysis of E2a reporter gene assays
293 cells (1  106) in six-well dishes were cotrans-
fected using the calcium phosphate precipitation proce-
dure with 1 g of pE2a-luc or pE2a-Cat plasmid and 2 g
of the individual Rep-expressing plasmids. Forty-eight
hours posttransfection, cells were harvested, total cellu-
lar extracts prepared, and protein concentrations deter-
mined using the Bio-Rad DC assay. Luciferase activity
was determined using a luciferase reporter assay sys-
tem according to the manufacturer’s protocol (Promega).
Cat enzyme assays were performed and analyzed by
thin-layer chromatography as described (Ausubel et al.,
1989).
Purification of Rep68 and Rep68PNB
Purification of Rep68 from E. coli cultures containing
pStumpRep68His was accomplished according to Young
et al. (2000), with some modifications. One-liter cultures
of pStumpRep68 or pStumpRe68-PNB-containing E. coli
were grown and induced and cellular lysates prepared
as described by Young et al. The crude cell lysates were
collected, glycerol was added to 20% (v/v), and the ly-
sates were applied to a Ni2-nitriloacetic acid (NTA)
column (bed volume 2.5 ml) that was equilibrated with 50
mM Na2HPO4, pH 8.1, 1 M NaCl, 0.1% Tween 20, 10 mM
-mercaptoethanol (BME), 50 mM imidazole, pH 7.0, and
20% (v/v) glycerol. The column was washed with 5 col-
umn volumes of 50 mM NaH2PO4, pH 6.0, 1 M NaCl, 0.1%
Tween 20, 10 mM BME, 100 mM imidazole, pH 7.0, 20%
(v/v) glycerol, 0.5 g/ml leupeptin, 0.7 g/ml pepstatin A,
and 0.1 mM PMSF. Rep68His was eluted with a linear
gradient of 0.1 to 1 M imidazole in Na2HPO4, pH 8.1, 20%
(v/v) glycerol, 0.5 g/ml leupeptin, 0.7 g/ml pepstatin A,
0.1 mM PMSF, 10 mM BME, 1 M NaCl, and 0.1% Tween
20. The column fractions were collected, quickly frozen in
dry ice, and stored at 70°C, after aliquots were taken
for gel electrophoresis and Western blot analysis. Col-
umn fractions containing Rep68 were thawed, combined,
and dialyzed against 50 mM Tris–HCl, pH 7.5, 50 mM
NaCl, 20% (v/v) glycerol, 0.1 mM EDTA, 0.1% Tween 20,
and 10 mM BME at 4°C for 2 h. The buffer was changed
twice and final dialysis of the sample was done in the
same buffer except that BME was substituted with 0.1
mM DTT. The dialyzed sample was applied to a Q-
Sepharose column (bed volume 10 ml) equilibrated with
50 mM Tris–HCl, pH 7.5, 20% (v/v) glycerol, 1 mM EDTA,
1 mM DTT, and 1 mM PMSF. The column was washed
with 10 bed volumes of the equilibration buffer and
eluted with a linear gradient made of 50 mM–1 M NaCl
in equilibration buffer at a flow rate of 1 ml/min. Column
fractions were collected and their optical densities were
determined at 280. Equal aliquots were taken from each
fraction for gel electrophoresis and Western blot analysis
and the fractions were stored at 70°C. Fractions of
interest were combined and concentrated in an Amicon
concentration device (mol wt cut-off 50,000) and sub-
jected to a Sephacryl S-300 gel filtration column (bed
volume 40 ml) that was equilibrated with 50 mM Tris–
HCl, pH 7.5, 20% (v/v) glycerol, 200 mM NaCl, 1 mM
EDTA, 1 mM DTT, and 1 mM PMSF. The column was
eluted with the same buffer at a flow rate of 0.5 ml/min.
Fractions were collected and analyzed by SDS–PAGE
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immunoblot analysis to identify fractions containing the
Rep68His protein.
Rep68PNB was purified by following the above proto-
col except that the protein was passed over two Ni2-
NTA columns instead of the Q-Sepharose and Sephacryl
300 columns.
In vitro transcription of Ad MLP
HeLa nuclear extracts were purchased from Promega
or were prepared following published procedures (Dig-
nam et al., 1983). All steps of the in vitro reactions were
performed as recommended in the manufacturer’s pro-
tocol (Promega Corp.) using [-32P]UTP (3000 Ci/mmol).
XbaI-linearized pTIGL (1.2 g) or 0.2 g of circular pTIGL
was used as transcription template. Purified Rep68 or
Rep68-PNB was added to final concentrations of 0.032,
0.064, 0.096, and 0.128 g/l. In vitro-synthesized RNA
was phenol–chloroform and chloroform extracted, etha-
nol precipitated, and analyzed by gel electrophoresis in a
5% polyacrylamide gel containing 7 M urea, 45 mM Tris,
45 mM boric acid, and 1 mM EDTA, pH 8.0. The gel was
then dried and exposed to X-ray film.
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